NASDAQ:GRFS - GRIFOLS S A/S Stock Price, News, & Analysis

Get Started

$18.73 -0.37 (-1.94 %)

(As of 03/22/2019 04:00 PM ET)

Previous Close$19.10

Today's Range$18.64 - $18.93

52-Week Range$17.42 - $24.97

Volume445,256 shs

Average Volume831,664 shs

Market Capitalization$12.88 billion

P/E Ratio17.03

Dividend Yield1.83%

Beta1.06

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GRFS

Previous Symbol

CUSIPN/A

CIK1438569

Webwww.grifols.com

Phone34-93-571-2200

Debt

Debt-to-Equity Ratio1.30

Current Ratio2.77

Quick Ratio1.22

Price-To-Earnings

Trailing P/E Ratio17.03

Forward P/E Ratio16.01

P/E Growth1.36

Sales & Book Value

Annual Sales$5.30 billion

Price / Sales2.43

Cash Flow$1.3854 per share

Price / Cash Flow13.52

Book Value$8.07 per share

Price / Book2.32

Profitability

EPS (Most Recent Fiscal Year)$1.10

Net Income$704.63 million

Net Margins16.55%

Return on Equity18.32%

Return on Assets6.24%

Miscellaneous

Employees18,296

Outstanding Shares687,554,000

Market Cap$12.88 billion

Next Earnings Date3/27/2019 (Estimated)

OptionableOptionable

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a special dividend on Thursday, November 8th. Stockholders of record on Monday, December 3rd will be paid a dividend of $0.2283 per share on Tuesday, December 11th. This represents a dividend yield of 2.25%. The ex-dividend date of this dividend is Friday, November 30th. This is a boost from GRIFOLS S A/S's previous special dividend of $0.01. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

Shares of GRIFOLS S A/S split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for GRIFOLS S A/S.

What price target have analysts set for GRFS?

6 analysts have issued 12-month price targets for GRIFOLS S A/S's shares. Their forecasts range from $19.00 to $19.00. On average, they expect GRIFOLS S A/S's stock price to reach $19.00 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for GRIFOLS S A/S.

What is the consensus analysts' recommendation for GRIFOLS S A/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

Headlines about GRFS stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GRIFOLS S A/S earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future.

Who are some of GRIFOLS S A/S's key competitors?

Some companies that are related to GRIFOLS S A/S include Allergan (AGN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Mylan (MYL) and Merck KGaA (MKGAF).

What other stocks do shareholders of GRIFOLS S A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Allergan (AGN), Exxon Mobil (XOM), NVIDIA (NVDA), Nektar Therapeutics (NKTR), Celgene (CELG), Alibaba Group (BABA), Jazz Pharmaceuticals (JAZZ), Energy Transfer LP Unit (ET) and Biogen (BIIB).

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:

Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 55)
Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 42)
Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (1.96%), AKO Capital LLP (1.79%), First Trust Advisors LP (0.68%), Bank of New York Mellon Corp (0.65%), Norges Bank (0.46%) and Millennium Management LLC (0.24%).

Which major investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Natixis Advisors L.P., Gladstone Capital Management LLP, Bank of New York Mellon Corp, FMR LLC, Great West Life Assurance Co. Can, Hsbc Holdings PLC, BlackRock Inc. and GABELLI & Co INVESTMENT ADVISERS INC..

Which major investors are buying GRIFOLS S A/S stock?

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, AKO Capital LLP, Impax Asset Management Group plc, Millennium Management LLC, Two Sigma Investments LP, OLD Mission Capital LLC, Two Sigma Advisers LP and FNY Investment Advisers LLC.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $18.73.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $12.88 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.10 on an earnings per share basis. GRIFOLS S A/S employs 18,296 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is http://www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]

MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)

Community Ranking:		2.2 out of 5 ( )
Outperform Votes:		236 (Vote Outperform)
Underperform Votes:		302 (Vote Underperform)
Total Votes:		538

MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 3/23/2019 by MarketBeat.com Staff